Your sleep may be hiding an early clue to Alzheimer’s

 Could subtle changes during sleep reveal vulnerability to Alzheimer's disease years before memory problems become noticeable? Researchers at ULiège, supported by the Stop Alzheimer's Foundation, are investigating whether the sleeping brain may contain early clues.

Scientists from the University of Liège (GIGA Neurosciences) examined sleep patterns in more than 500 healthy people. Among participants in middle age, more frequent nighttime micro awakenings were associated with a higher genetic risk of developing Alzheimer's disease. That relationship was not detected among younger adults.

The findings, published in the journal Sleep, raise the possibility that sleep measurements could eventually help researchers identify people who may be more vulnerable to Alzheimer's before symptoms develop.

Looking for Alzheimer's Clues Before Symptoms

Researchers have spent years investigating connections between disturbed sleep and neurodegenerative diseases. The University of Liège study adds another piece to that research by suggesting that the relationship between sleep and Alzheimer's risk may begin well before recognizable symptoms emerge.

Because genetics play a partial role in Alzheimer's disease (Alzheimer's disease is neither purely hereditary nor entirely independent of genes), the researchers calculated a polygenic risk (i.e., summarizing the combined influence of your genes on your probability of developing a given disease in a single figure) for more than 500 healthy participants.

Most were young adults (aged 18 to 31), while the study also included an older group (aged 50 to 69). Importantly, the polygenic risk measured in the study remained low and cannot determine whether any particular person will eventually develop Alzheimer's disease.

The researchers then compared these genetic risk estimates with different characteristics of each participant's sleep.

Tiny Awakenings During the Night

The analysis revealed an association between genetic risk for Alzheimer's disease and the frequency of nighttime micro awakenings. These are very brief bursts of brain activity that can interrupt the normal sleep cycle without causing someone to become fully awake.

Among the younger participants, researchers found no connection between these micro awakenings and Alzheimer's genetic risk. A different pattern appeared in the older group. Participants who experienced more frequent micro awakenings also tended to have higher genetic risk, despite being healthy, relatively young and free of Alzheimer's symptoms.

"These micro-awakenings are therefore not insignificant," emphasizes Puneet Talwar, a researcher at the GIGA ULiège laboratory, "certain profiles could promote the accumulation of proteins involved in Alzheimer's disease and be associated with increased vulnerability."

A Tiny Brain Region Draws Attention

The researchers also examined the locus coeruleus, a tiny area deep within the brainstem that is roughly the size of a grain of rice. It plays an important role in regulating wakefulness, attention, and sleep.

"This region is difficult to observe, but it appears to play a role in the early mechanisms linked to the disease," explains Gilles Vandewalle, co-director of the GIGA CRC In Vivo Imaging technology platform and Fund for Scientific Research - FNRS Research Director at ULiège.

In 2025, a preliminary study carried out with the 7-Tesla MRI scanner at the ULiège platform allowed the team to examine the locus coeruleus in greater detail. The researchers found that characteristics of sleep quality (speed of falling asleep, depth) were associated with the condition of the brainstem beginning at a young age.

They also found that healthy functioning of the locus coeruleus was related to the quality of REM sleep, a stage of sleep that plays an important role in memory.

The locus coeruleus is especially interesting to Alzheimer's researchers because it is among the earliest brain regions where abnormal protein deposits can appear. Such deposits may begin accumulating as early as adolescence, although scientists still do not fully understand what these early changes mean.

Could Sleep Become an Early Alzheimer's Marker?

Taken together, the findings point toward possible new approaches for Alzheimer's screening and prevention. In the future, analyzing sleep could potentially complement other methods for identifying people who may be vulnerable to the disease before symptoms become apparent.

"Sleep could become an accessible marker for the early identification of vulnerable individuals," adds Gilles Vandewalle.

Researchers are also interested in whether improving sleep could eventually help prevent or slow disease progression among people with a genetic predisposition to Alzheimer's.

"This research shows that sleep is not only an indicator of health, but also a potential lever for intervention," adds Lucie Leroux, head of French-speaking activities at the Stop Alzheimer's Foundation.

More than 220,000 people in Belgium are affected by Alzheimer's disease. For now, however, the new findings show statistical associations rather than proof that particular sleep patterns cause or predict the disease. Additional research will be needed to confirm the results, and the findings cannot currently be used to determine whether an individual will develop Alzheimer's.

Even so, the research provides another glimpse into changes that may occur long before Alzheimer's becomes clinically visible and underscores the value of basic research aimed at understanding and, eventually, anticipating the disease.

Journal Reference:

1. Nasrin Mortazavi, Puneet Talwar, Ekaterina Koshmanova, Roya Sharifpour, Elise Beckers, Alexandre Berger, Islay Campbell, Ilenia Paparella, Fermin Balda, Ismael Dardour Hamzaoui, Christian Berthomier, Christine Bastin, Christophe Phillips, Pierre Maquet, Fabienne Collette, Mikhail Zubkov, Laurent Lamalle, Gilles Vandewalle. REM sleep quality is associated with balanced tonic activity of the locus coeruleus during wakefulness. Journal of Biomedical Science, 2025; 32 (1) DOI: 10.1186/s12929-025-01127-9

Courtesy:

University of Liège. "Your sleep may be hiding an early clue to Alzheimer’s." ScienceDaily. ScienceDaily, 28 August 2026. <www.sciencedaily.com/releases/2026/08/260828005218.htm>. 

 

 

 

 

 

 

A cancer therapy put severe rheumatoid arthritis into remission

 Immunotherapies such as CAR T-cell therapy were originally developed mainly to fight cancer. But scientists are now investigating whether these personalized treatments, made from a patient's own immune cells, could also help treat or even potentially cure autoimmune diseases.

Researchers at Charité - Universitätsmedizin Berlin have now tested CAR T-cell therapy in six people with particularly severe rheumatoid arthritis. The world's first clinical trial of its kind, reported in Nature Medicine, produced encouraging early results. Disease activity fell substantially in every participant, and by the end of the observation period, three patients no longer needed rheumatoid arthritis medication.

Why Rheumatoid Arthritis Can Be So Difficult To Treat

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system mistakenly attacks the joints. Repeated inflammation causes swelling and can eventually damage the joints.

Existing medications are often effective at controlling inflammation, but they generally do not cure the disease. As a result, many patients need lifelong treatment with anti-inflammatory drugs and medications that suppress the immune system, which can also cause side effects.

For some people, even newer therapies do not work well enough. Doctors describe these cases as treatment-refractory rheumatoid arthritis. Patients can continue to experience pain, limited mobility, and major reductions in quality of life despite trying multiple treatments.

"One reason could be disease-driving B cells - memory cells of the adaptive immune system that may survive in the lymph nodes, bone marrow or joint tissue after an infection, where they produce harmful antibodies directed against the body's own tissues and repeatedly reignite the inflammation," explains Prof. David Simon, who designed the trial for this patient group together with Prof. Gerhard Krönke at Charité's Department of Rheumatology and Clinical Immunology.

The researchers are testing whether CAR T cells can seek out these disease-driving B cells even when they are buried deep within body tissues. Their goal is to eliminate as much of the abnormal B-cell memory as possible and effectively give the B-cell system a new start.

Using Cancer Immunotherapy To Reset the Immune System

CAR T cells were first developed as a cancer treatment, but their potential uses are expanding. In cancer therapy, a patient's immune cells are modified so they can recognize and destroy tumor cells. For autoimmune diseases, scientists instead want to direct those engineered cells toward immune cells that help sustain the disease.

"The identifying marker on many B cells, both abnormal B cells in cancers of the blood or lymphatic system and disease-driving B cells in rheumatoid arthritis, is the surface molecule CD19. You could think of it as a kind of 'name tag'," explains David Simon. "To enable CAR T cells to detect and eliminate the disease-causing cells, we equip patients' own immune cells with a receptor that acts like a search sensor for CD19."

To produce this form of CD19 CAR T-cell therapy, doctors first collect T cells from the patient's blood. T cells are immune cells that normally help recognize and destroy infected or abnormal cells.

Scientists then genetically modify those T cells in the laboratory. The cells receive a chimeric, or artificial, antigen receptor known as a CAR, which is designed to bind specifically to CD19.

Before receiving the modified cells, patients undergo a short course of preparatory chemotherapy. This temporarily lowers the number of certain immune cells, creating room for the CAR T cells to multiply and function effectively.

The engineered cells are then returned to the patient in a single infusion. Once inside the body, they search for cells carrying CD19 and attack them. This temporarily removes all CD19-positive B cells, including long-lived disease-driving cells in the joints that can otherwise be difficult to reach. By clearing out those cells, the treatment may allow the immune system to reset.

First Trial in Severe Rheumatoid Arthritis

For the first clinical trial evaluating both the safety and effectiveness of CD19 CAR T-cell therapy in rheumatoid arthritis, the Charité team initially enrolled six patients with especially severe disease.

The group included three women and three men between the ages of 31 and 69. During the previous decade, they had received as many as eight targeted or biologic therapies, but none had controlled their disease adequately.

Researchers wanted to learn whether CAR T cells could reach the disease-driving B cells inside the joints and whether the approach could do so safely.

The first phase of the COMPARE trial produced results the team considers highly encouraging.

"Disease activity decreased markedly in all six patients. During follow-up of up to one year, three patients were in sustained remission without any medication for rheumatoid arthritis," reports Gerhard Krönke, who leads the joint Clinical Rheumatology research group at Charité and the German Rheumatology Research Center (DRFZ), a Leibniz Institute. "This is particularly remarkable given that none of the established treatments had previously been able to relieve their symptoms adequately."

CAR T Cells Reached Hidden Disease Reservoirs

The treatment appeared to do more than temporarily reduce inflammation in the joints. Researchers found that the modified immune cells also reached and eliminated disease-promoting B cells in deeper locations, including the bone marrow, lymph nodes, and joint tissue.

During regular follow-up visits over the following 12 months, levels of the autoantibodies associated with rheumatoid arthritis dropped sharply.

David Simon adds: "When the B-cell system later recovered, predominantly naïve B cells that had not yet been shaped by the disease returned. In contrast, the B cells directed against the body's own tissues that had been present before treatment were no longer detectable in almost all patients, an indication that the treatment may indeed be able to reset the pathological immune memory."

Importantly, antibodies generated by earlier vaccinations, including those against chickenpox and tetanus, could still be detected. That suggests protective antibody memory was largely preserved even though the therapy caused a profound temporary depletion of B cells.

Researchers still need to determine whether the therapy has any longer-term effects on the immune system.

Promising Results, but the Therapy Remains Experimental

The trial suggests that a single CAR T-cell treatment can, in some patients, produce a sustained period without symptoms or rheumatoid arthritis medication. This state of disease inactivity is known as remission.

For carefully selected patients whose rheumatoid arthritis does not respond adequately to available treatments, researchers hope it may eventually be possible to directly reset pathological immune memory and stop the ongoing inflammation rather than continuously suppressing it with medication.

However, CAR T-cell therapy for autoimmune diseases, including rheumatoid arthritis, is still experimental. Researchers do not yet have long-term experience with the treatment.

Responses also differed among the six participants. Some did not achieve a complete response, and one patient's disease returned after an initial period of medication-free remission.

So far, however, the researchers consider the safety findings encouraging.

"After the participants received the CD19 CAR T cells, we observed only a temporary, mild-to-moderate cytokine release syndrome (CRS) in all participants, which was readily manageable. There were no severe neurological complications or other serious adverse events, and infections were rare," explains Dr. Marie Luise Hütter-Krönke, Medical Director of the Hematology Early Clinical Trial Unit at Charité's Department of Hematology, Oncology and Cancer Immunology.

A Larger Comparison Is Next

The second phase of the trial will include ten additional patients. Researchers plan to compare CAR T-cell therapy with an already approved rheumatoid arthritis drug that also targets B cells.

The comparison should help determine whether CAR T cells produce stronger or longer-lasting effects and whether they truly reset immune memory.

If these results are confirmed in this phase and in future larger studies, CAR T-cell therapy could eventually offer another option for people with severe rheumatoid arthritis whose lives are significantly affected by the disease and who currently have no adequate treatment.

About the Study

The first of the two phases of the COMPARE study was designed to assess the safety and effectiveness of CD19 CAR T-cell therapy in treatment-refractory rheumatoid arthritis.

Major contributors included researchers from Charité's Department of Rheumatology and Clinical Immunology and the Department of Hematology, Oncology and Cancer Immunology at Campus Benjamin Franklin, along with scientists from the Cluster of Excellence ImmunoPreCept, the German Rheumatology Research Center (DRFZ), a Leibniz Institute, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.

The study was initiated and designed at Charité and also received support from Kyverna Therapeutics. The immunotherapy company had no role in designing the study, collecting or analyzing the data, or presenting the results.

Journal Reference:

1. Fredrik N. Albach, Marie C. Rehm, Marie Luise Hütter-Krönke, Thanh Hang Le, Julia M. Giezen, Murat Torgutalp, Arne Sattler, Ioanna Minopoulou, Robert Biesen, Edgar Wiebe, Vincent Casteleyn, Thorben Witte, Christian Furth, Jan Zernicke, Melanie Nuesch Germano, Johan Verhagen, Artur Wilhelm, Maria Dzamukova, Klaus Engel, Simon Schallenberg, Aimo Kannt, Nicole Ziegler, Michaela Fehringer, Udo Schneider, Nadine Unterwalder, Mark Beling, Alexander Pfeil, Elpida Phithak, Martin Krusche, Olaf Penack, Tobias Alexander, Werner Stenzel, Manfred Wuhrer, Kamran Movassaghi, Thomas Dörner, Eicke Latz, Thomas Vogl, Antonia Busse, Georg Schett, Hans Ulrich Scherer, Rene E. M. Toes, Arnd Kleyer, Ulrich Keller, Lars Bullinger, David Simon, Gerhard Krönke. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nature Medicine, 2026; DOI: 10.1038/s41591-026-04603-3

Courtesy:

Charité - Universitätsmedizin Berlin. "A cancer therapy put severe rheumatoid arthritis into remission." ScienceDaily. ScienceDaily, 29 August 2026. <www.sciencedaily.com/releases/2026/08/260828082330.htm>. 

 

 

 

 

 

Researchers unveil sustainable spirulina solution to vitamin B12 deficiency

Scientists have found a way to grow Spirulina that produces biologically active vitamin B12 at levels comparable to beef, potentially overcoming one of the biggest nutritional limitations of this widely promoted algae.

The research, published in the scientific journal Discover Food, was led by Dr. Asaf Tzachor, Founder and Academic Director of the Aviram Sustainability and Climate Program at Reichman University, together with researchers from Iceland, Denmark and Austria. Using advanced biotechnology and carefully controlled light conditions, the team produced carbon-neutral, nutrient-rich Spirulina biomass containing active vitamin B12. According to the researchers, this is the first time biologically active vitamin B12 has been reported in Spirulina.

A Global Vitamin B12 Problem

Vitamin B12 is an essential micronutrient involved in several critical processes in the body, including red blood cell formation and normal nervous system function. More than a billion people worldwide are estimated to have low levels of the vitamin.

For many people, meat and dairy products are important dietary sources of B12. The recommended intake cited by the researchers is 2.4 µg/day. However, producing animal-based foods at the scale required to meet global demand also carries environmental costs, which has driven interest in more sustainable alternatives.

Spirulina blue green algae (Arthrospira platensis) has often been promoted as one such option because it is nutrient dense and can be cultivated with a relatively small environmental footprint. But there has been a major obstacle.

Traditional Spirulina contains much of its B12 in the form of pseudo-vitamin B12. Although chemically similar to the vitamin humans need, this form is not bioavailable to people, meaning the body cannot effectively use it. That limitation has prevented conventional Spirulina from serving as a reliable replacement for animal-sourced vitamin B12.

Using Light to Change Spirulina's Nutrition

To address that problem, researchers from Reichman University, University of Natural Resources and Life Sciences, Vienna, Ruppin Academic Center, Danish Technological Institute, and MATIS, Iceland, carried out an exploratory study of a biotechnology platform developed by VAXA Technologies in Iceland.

The team examined the system's engineering design, its inputs (such as energy), and the nutritional composition of the biomass it produced.

A central feature of the technology is photonic management (modified light conditions). By changing the light environment in which Spirulina grows, the researchers were able to encourage production of biologically active vitamin B12.

The cultivated Spirulina also contained other bioactive compounds associated with antioxidant, anti-inflammatory, and immune-boosting properties.

Most notably, the resulting carbon-neutral biomass contained 1.64 µg of active vitamin B12 per 100 grams, compared with 0.7-1.5 μg per 100 grams in beef.

Dr. Asaf Tzachor explains, "the findings demonstrate that photosynthetically controlled Spirulina can produce desirable levels of active vitamin B12, offering a sustainable alternative to traditional animal-source foods."

Could Spirulina Supply Vitamin B12 at Scale?

The researchers also explored what could happen if the system were expanded far beyond its current scale.

In one scenario, reallocating electricity currently used by heavy industry in Iceland could support production of 277,950 tonnes of Spirulina biomass each year. The researchers estimate that this amount would contain about 4555 grams of active vitamin B12 annually.

According to their calculations, that quantity could provide the recommended dietary allowance (RDA) for more than 13.8 million children aged 1-3.

More ambitious production scenarios could potentially supply enough vitamin B12 to meet the RDA for more than 26.5 million children aged 1-3 and more than 50 million children aged 0-6 months.

These figures are projections based on possible scale-up scenarios rather than existing production levels, but they illustrate the nutritional potential the researchers see in the technology.

A More Sustainable Source of an Essential Vitamin

If the approach can be successfully expanded, photosynthetically controlled Spirulina could provide another route for addressing vitamin B12 deficiency while reducing some dependence on meat and dairy production.

The work also highlights how biotechnology can alter the nutritional properties of microorganisms and other rapidly growing food sources. Rather than simply cultivating conventional Spirulina, researchers are changing the conditions under which it grows to encourage production of specific compounds that are useful to humans.

The findings represent a step toward developing more sustainable sources of essential nutrients, although further research and larger-scale production will be needed to determine how the technology could fit into real-world food systems.

Reichman University and the Aviram Foundation established the Aviram Sustainability and Climate Program in response to growing environmental and public health challenges around the world. The program trains students from a range of disciplines to develop strategies for addressing resource scarcity, climate change, and extreme weather events, as well as food, water, and energy crises.

 

Journal Reference:

1. A. Tzachor, S. P. van den Oever, H. K. Mayer, M. Asfur, A. Smidt-Jensen, M. Geirsdóttir, S. Jensen, B. O. Smárason. Photonic management of Spirulina (Arthrospira platensis) in scalable photobioreactors to achieve biologically active unopposed vitamin B12. Discover Food, 2024; 4 (1) DOI: 10.1007/s44187-024-00152-1

Courtesy:

Reichman University. "Researchers unveil sustainable spirulina solution to vitamin B12 deficiency." ScienceDaily. ScienceDaily, 30 August 2026. <www.sciencedaily.com/releases/2026/08/260829035227.htm>. 

 

 

 

Widely prescribed blood pressure drugs linked to 33% higher kidney risk in type 2 diabetes

 

New findings presented at the 63rd ERA Congress suggest that a commonly prescribed group of blood pressure drugs may be linked to worse kidney outcomes in people with type 2 diabetes (T2D), including patients already taking newer medications designed to protect kidney function.

The medications, known as dihydropyridine calcium-channel blockers (DCCBs), lower blood pressure by relaxing blood vessels. They are often prescribed as second-line treatments for people with diabetic kidney disease (DKD). In the new study, patients who took DCCBs in addition to standard therapies experienced a significantly greater risk of major adverse kidney events than patients treated with other blood pressure medications.

Protecting the Kidneys in Type 2 Diabetes

DKD is among the most common causes of kidney failure worldwide. The condition develops as prolonged high blood sugar damages tiny blood vessels within the kidneys, gradually interfering with their ability to remove waste from the bloodstream. Keeping blood pressure under control is a key part of managing the disease because elevated blood pressure can speed up this damage.

Treatment for DKD has changed considerably in recent years with the introduction of two important classes of medication. Renin-angiotensin system (RAS) inhibitors lower blood pressure while also reducing pressure inside the kidney's filtering structures. Sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially developed to treat diabetes, but they are now also recognized for their ability to protect kidney function and lower the risk of kidney failure. The two drug classes are now part of standard treatment for many people with DKD.

Study Tracks More Than 31,000 Patients

Researchers examined health data from 31,031 adults with T2D between 2016 and 2021. Every participant was receiving both RAS and SGLT2 inhibitors. Of the total group, 12,172 (39.2%) were also taking DCCBs, while 18,859 (60%) were being treated with other antihypertensive medications. The median follow-up period was approximately 3.5 years.

After accounting for differences in patients' initial clinical and demographic characteristics, the researchers found that DCCB use was associated with a 33% greater risk of a major adverse kidney event (R 1.33, 95%, CI 1.03-1.73).

Researchers classified these events as either a major loss of kidney filtration capacity, involving a decline of 40% or more in estimated glomerular filtration rate (eGFR), the standard measure of kidney function, or progression to end-stage kidney disease that required dialysis or transplantation.

"DCCBs are widely used as second-line blood pressure treatments in patients with DKD," said Dr. Timna Agur, lead author of the study. "Our findings raise important questions about whether these medications are always the best option for patients already receiving modern kidney-protective therapies."

Why DCCBs Could Affect Kidney Function

The researchers suggest that the association may be related to how DCCBs alter blood flow through the kidneys. In DKD, the kidneys are already dealing with elevated pressure and hyperfiltration, a condition in which their filtering structures are placed under excessive strain.

DCCBs may relax the blood vessels that carry blood into these filtering units more strongly than they affect the vessels carrying blood away. According to the researchers, this imbalance could increase pressure inside the filtering structures and potentially contribute to continued kidney damage.

"We initially thought the kidney-protective effects of SGLT2 inhibitors might counterbalance the potential harms associated with DCCBs," said Dr. Agur. "However, the increased risk of kidney disease progression appeared to persist even in this group."

More Research Is Needed

Because the study was observational, the researchers emphasize that it cannot show that DCCBs directly caused the poorer kidney outcomes. Still, they say the association deserves attention because these medications are so frequently prescribed to people with DKD.

"Further prospective studies and randomized controlled trials are needed to confirm these observations and better define the safest blood pressure treatment strategies for patients with DKD," concluded Dr. Agur. "However, given how commonly these medications are prescribed, any increase in kidney risk could have important implications for large numbers of patients with DKD."

Story Source:

Materials provided by European Renal Association (ERA). Note: Content may be edited for style and length.

 

Courtesy:

European Renal Association (ERA). "Widely prescribed blood pressure drugs linked to 33% higher kidney risk in type 2 diabetes." ScienceDaily. ScienceDaily, 18 August 2026. <www.sciencedaily.com/releases/2026/08/260816044844.htm>. 

 

 

 

 

Scientists turn probiotic bacteria into tiny drug factories for pancreatic cancer

Cancer immunotherapy has dramatically changed how doctors treat many forms of cancer, yet pancreatic cancer has remained particularly resistant to these advances. A major obstacle is the environment that develops around pancreatic tumors. These tumors often create a "cold" tumor microenvironment that blocks immune cells from launching an effective attack.

Researchers at the University of Chicago have now developed a new approach that could help overcome this problem. In a study published in Science Advances, the team used BifidoSumIL-2, an engineered strain of Bifidobacterium longum, a probiotic bacterium naturally found in the gut, to carry an immune-stimulating treatment directly into tumors.

In animal models, the therapy slowed the growth of pancreatic tumors by selectively activating T cells that fight cancer. Its effects became even stronger when researchers combined it with chemotherapy, radiotherapy or immunotherapy. The findings suggest that BifidoSumIL-2 could eventually provide a new way to improve how pancreatic tumors respond to treatment.

Using Bacteria to Deliver Cancer Therapy

"A big unmet medical need has been pancreatic cancer, and so that was going to be our mountain to climb," said Ralph Weichselbaum, MD, the Daniel K. Ludwig Distinguished Service Professor and Chair of Radiation and Cellular Oncology at the University of Chicago.

BifidoSumIL-2 was created to release a modified version of interleukin-2 (IL-2) once it reaches a tumor. IL-2 is a potent immune signaling molecule that activates T cells involved in attacking cancer. Conventional IL-2 treatment, however, can produce serious side effects and can also stimulate immune cells that actually weaken the antitumor response.

The researchers sought to avoid these problems by using SumIL-2, a modified form of IL-2 engineered to more precisely activate cancer-fighting T cells while reducing stimulation of regulatory T cells. They then placed SumIL-2 inside Bifidobacterium longum so that the therapeutic molecule could be concentrated within tumors instead of throughout the body.

Developing the treatment required scientists from several disciplines to work together, including specialists in microbiology, synthetic biology, oncology, and immunology.

"This was a highly interdisciplinary effort," said Mark Mimee, PhD, Assistant Professor of Microbiology at the University of Chicago. "We had to bring together people who understand bacteria, people who understand tumors, and people who understand the immune system to make something like this possible."

Why Bifidobacterium Can Target Tumors

Bifidobacterium offered the researchers an unusual advantage as a delivery system. The bacterium grows in anaerobic environments, meaning places with very little oxygen. Low oxygen levels are common inside many solid tumors, including pancreatic tumors, while healthy tissues generally contain more oxygen and are therefore less suitable for the bacteria.

"Bifidobacterium is an obligate anaerobe, so it doesn't grow in the presence of oxygen," Mimee said. When the bacteria are injected systemically, they are cleared from healthy tissues with abundant oxygen. Inside the low-oxygen regions of tumors, however, they can become active.

That preference allows the engineered bacteria to function as microscopic drug factories inside tumors. Once there, they produce SumIL-2 where the treatment is needed rather than broadly throughout the body. Researchers also noted that Bifidobacterium has shown a favorable safety profile in preclinical models and is already well known as a probiotic organism. It is commonly present in yogurt and is generally recognized as a safe, off-the-shelf probiotic.

Engineering the organism was not simple.

"Bifidobacterium is not the easiest organism to work with," Mimee said. "It's anaerobic, it grows slowly, and the genetic tools for manipulating it are much more limited compared to model bacteria like E. coli. A lot of the work was just figuring out how to reliably engineer it."

Stronger Results With Combination Treatments

Tests in animal models showed that BifidoSumIL-2 preferentially gathered inside tumors, stimulated immune activity, and slowed the growth of pancreatic cancer. It also changed the tumor microenvironment in a potentially beneficial way by increasing the activity of cancer-fighting CD8+ T cells.

The results improved further when BifidoSumIL-2 was paired with established cancer treatments. Combining the bacterial therapy with chemotherapy, radiation therapy, or anti-PD-L1 immunotherapy led to better tumor control and longer survival than the individual treatments achieved on their own.

"This combination potential is one of the study's most important findings; BifidoSumIL-2 not only works by itself -- it works with radiotherapy, chemotherapy, and immunotherapy," Weichselbaum said.

Despite the encouraging findings, BifidoSumIL-2 has not been tested in humans. Future research will need to examine its long-term safety, the possibility of effects outside the intended tumor, how long the immune response lasts, and whether the bacteria might eventually be given orally instead of through injection. The researchers also want to investigate whether the strategy can be combined with newer pancreatic cancer treatments, including KRAS inhibitors.

The Growing "Bugs as Drugs" Approach

The research adds to growing interest in a strategy known as "bugs as drugs." By engineering probiotic bacteria to seek out tumors and produce therapies directly inside them, scientists may be able to concentrate powerful immune treatments where they are most useful while reducing unwanted effects elsewhere in the body.

The study, "Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy" was supported by funds from the Ludwig Foundation and the National Institutes of Health.

Additional authors include Jaehyun Lee, Kaiting Yang, Christina Nowicki, Wei Liu, Emile Naccasha, and Hua Liang from the University of Chicago; Zhichen Sun from the University of Texas Southwestern, Dallas; and Yang-Xin Fu from Tsinghua University, Beijing, China.

UChicago Medicine and the Biological Sciences Division continue to be at the forefront of cancer care and research. In April 2027, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion, Chicago's first freestanding cancer pavilion, to bring advanced diagnostics, innovative treatments, translational discoveries, and comprehensive support to patients and the community.

Journal Reference:

1. Jaehyun Lee, Kaiting Yang, Christina A. Nowicki, Wei Liu, Kangdi Li, Emile Naccasha, Zhichen Sun, Yang-Xin Fu, Hua Liang, Ralph R. Weichselbaum, Mark Mimee. Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Science Advances, 2026; 12 (30) DOI: 10.1126/sciadv.adz1388

Courtesy:

University of Chicago Medical Center. "Scientists turn probiotic bacteria into tiny drug factories for pancreatic cancer." ScienceDaily. ScienceDaily, 19 August 2026. <www.sciencedaily.com/releases/2026/08/260816044830.htm>.

 

 

 

 

 

 

Coffee drinkers have less fat, more muscle, and surprising hormone differences

Coffee is consumed around the world every day, and earlier research has associated coffee drinking with a reduced risk of conditions including type 2 diabetes and cardiovascular disease. Scientists still do not fully understand the biological processes that might explain those connections. Now, new research from Finland suggests that regular coffee consumption is associated with healthier body composition, favorable metabolic markers, and distinct patterns involving sex hormones in men and women.

Researchers at the University of Oulu analyzed information from 2,264 people who were 46 years old and taking part in the Northern Finland Birth Cohort 1966. The team investigated how participants' usual coffee intake related to circulating metabolites, indicators of cardiometabolic risk, and sex hormone levels.

Coffee Drinkers Had Less Fat and More Muscle

People who consumed more coffee tended to have lower levels of both total body fat and visceral fat, along with greater skeletal muscle mass. These differences appeared even though participants with higher and lower coffee intake had a similar body mass index (BMI).

Higher coffee consumption was also associated with lower circulating concentrations of branched-chain amino acids in both men and women. When chronically elevated, these biomarkers have previously been associated with insulin resistance and a greater risk of developing type 2 diabetes.

Coffee Intake Was Linked to Different Hormone Patterns

Some of the clearest differences appeared among men. Greater coffee consumption was associated with a more favorable glucose-insulin profile, higher levels of total and bioavailable testosterone, and greater concentrations of sex hormone-binding globulin (SHBG). However, free testosterone and the free androgen index were modestly lower.

The hormonal associations were less extensive in women. Higher coffee consumption was mainly associated with increased SHBG and lower measures of free androgens.

"Coffee is consumed by millions of people every day, yet we still know surprisingly little about how it relates to our metabolism and hormones. What stood out in our findings was a distinct hormonal signature that didn't disappear even after we took into account BMI and lifestyle factors, with several of these associations differing between men and women," says Luca Verroest, lead author of the study and Doctoral Researcher at the University of Oulu.

Hormones Could Offer a Clue to Coffee's Health Links

The findings raise the possibility that hormonal pathways could help explain some of the previously observed relationship between coffee consumption and metabolic health. Because the research was observational, however, it cannot establish that drinking coffee directly caused any of the biological differences identified in the study.

The setting also makes the research especially relevant. Finland ranks among the world's highest coffee-consuming countries, with average annual consumption of approximately 11.8 kilograms (26 pounds) per person.

Researchers say the results offer a starting point for studies designed to determine whether coffee itself produces these biological changes and, if so, which compounds may be responsible. Scientists are currently investigating these questions using animal models, with the longer-term aim of moving toward human intervention studies.

Additional research will be necessary before the findings can be used to shape dietary recommendations.

The study, "Associations of habitual coffee intake with testosterone and cardiometabolic markers: the Northern Finland Birth Cohort 1966 study," was published in the European Journal of Nutrition.

 

Journal Reference:

1. Luca Verroest, Jari Jokelainen, Shalini Choudhary, Jaroslaw Walkowiak, Toni Karhu, Saranya Palaniswamy, Juha Auvinen, Marjo-Riitta Jarvelin, Karl-Heinz Herzig, Ghulam Shere Raza. Associations of habitual coffee intake with testosterone and cardiometabolic markers: the Northern Finland birth cohort 1966 study. European Journal of Nutrition, 2026; 65 (5) DOI: 10.1007/s00394-026-04038-z

Courtesy:

University of Oulu, Finland. "Coffee drinkers have less fat, more muscle, and surprising hormone differences." ScienceDaily. ScienceDaily, 19 August 2026. <www.sciencedaily.com/releases/2026/08/260819041228.htm>.